ENSYSCE BIOSCIENCES INC

Ensysce Biosciences sees a steep 7.8% drop as its biotech hopes face market reality—high risk, low valuation, and uncertain future.

Ensysce Biosciences sees 4.21% rise, driven by CY200 orphan drug success and expanding Middle Eastern family‑office ties. Discover its growth strategy.

ENSC stock falls 0.8% as Ensysce Biosciences, a clinical‑stage biopharma tackling prescription abuse, trades at $0.52 with a 9.8 M market cap.